Status:
COMPLETED
Infusion Laboratory: Protocol 1 - Selegeline - 2
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Cocaine-Related Disorders
Eligibility:
All Genders
31-47 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the effects of selegiline on the subjective and physiological effects of cocaine challenge in chronic crack abusers, and to evaluate clinical safety issues pe...
Detailed Description
To develop a medication for the treatment of cocaine addiction using a medical human physio-neuro-psycho-immunology laboratory setting. To characterize this cocaine abusing population on a variety of ...
Eligibility Criteria
Inclusion Criteria:
M/F, ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
Key Trial Info
Start Date :
November 1 1994
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00000337
Start Date
November 1 1994
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Friends Research Institute
Los Angeles, California, United States, 90025